Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
br Introduction Arginase deficiency is a
2024-03-06
Introduction Arginase deficiency is a rare metabolic disorder resulting from a loss of arginase 1 (ARG1), the final enzyme in the urea cycle, which is the major pathway for the detoxification of ammonia in terrestrial mammals. ARG1 is expressed most prevalently in hepatocytes and red blood cells.
-
HMGN proteins are subject to extensive
2024-03-06
HMGN proteins are subject to extensive post-translational modifications which influence both their mode of binding to 2,4-Diacetylphloroglucinol and their functional activity. Like the other HMG protein families, HMGNs are substrates for many of the same enzymes that modify histone proteins (review
-
Regarding progression free survival analyzing clinical trial
2024-03-06
Regarding progression free-survival, analyzing 12 clinical trials, we demonstrated that the use of antiangiogenic treatment results in a statistically longer PFS with a pooled HR of 0.76 (95% CI 0.65–0.89, p test for heterogeneity (Q=58.4, pExo1 sale of improvement of PFS only is that after antiangi
-
br Conclusions In summary we report a
2024-03-06
Conclusions In summary, we report a novel preliminary finding of a potential racial difference in the association of Cd-content and AR expression in prostate cancer that will need to be confirmed in larger studies. Although the association of Cd and AR protein expression is not strong in tumor ti
-
br Conclusions br Transparency document br Acknowledgements
2024-03-06
Conclusions Transparency document Acknowledgements This work was supported by a grant from the European Commission FP6 “Neuroprion” – Network of Excellence and Royal Veterinary College Bioveterinary science research project funding. We thank Professor Alun Williams (Cambridge University) fo
-
APP is a member of
2024-03-06
APP is a member of a conserved protein family that also includes amyloid precursor-like proteins 1 and 2 (APLP1, APLP2).8, 9, 10 The proteins in this family are type I single-pass transmembrane Apoptozole australia with receptor-like structural features but not entirely clear cellular functions.11,
-
Synthesis of the pterin carboxamides was achieved as shown
2024-03-06
Synthesis of the pterin-7-carboxamides was achieved, as shown in , based on a previously reported method that utilizes DBU as a key additive to dissolve pterin in organic solvents and accelerate the reaction., With this method, the pterin-amino G007-LK synthesis conjugates (–) were readily obtaine
-
The results of cell culture models were further
2024-03-06
The results of cell culture models were further supported by in vivo studies in mice treated with PXR and/or AhR agonists, PCN and β-NF. In these mice, AhR-regulated cyp1a1, and cyp1a2 were suppressed by PXR activation as determined by real time Q-PCR (Fig. 3). The level of PXR mRNA was not changed
-
br Materials and methods br Results br Discussion Several
2024-03-06
Materials and methods Results Discussion Several major signaling and developmental pathways (e.g. EGFR, ALK, KRAS, TGFβ, Notch and Wnt/β-catenin) have been shown to be involved in lung carcinogenesis and they are being exploited as targets of the non-small cell lung cancer therapy (for revi
-
regadenoson With one exception all receptors for dopamine DA
2024-03-06
With one exception, all receptors for dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT), and norepinephrine are metabotropic receptors. The five metabotropic DA receptors (D1–D5) in the CNS are involved in motivation, pleasure, cognition, learning, memory, fine motor control, and modulate neuroen
-
DAergic as well as GABAergic and glutamatergic neurons
2024-03-06
DAergic, as well as GABAergic and glutamatergic neurons, send projections to target forebrain structures, such as the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), and support diverse functional roles (Carr and Sesack, 2000a, Carr and Sesack, 2000b, Omelchenko and Sesack, 2009, Taylor
-
Subsequently Palvimaki et al corroborated Ni and
2024-03-06
Subsequently, Palvimaki et al. (1999) corroborated Ni and Miledi's study by demonstrating that treatment with fluoxetine leads to 43% occupancy of the 5-HT2C receptors. Moreover, the affinity of fluoxetine for 5HT2C receptors (Ki 65 nM) is close to its affinity for 5-HT transporters (Ki 33 nM) (Ni a
-
Although experiments on animals and cells indicate that
2024-03-05
Although experiments on animals and cells indicate that antioxidant and free radical scavenging agents have protective effects against brain damage, the results of preclinical trials are not as encouraging. Edaravone is a type of free radical scavenging drug that was first used as a neuroprotective
-
somatostatin agonist The identification of novel kinase inhi
2024-03-05
The identification of novel kinase inhibitor scaffolds is highly desirable in order to develop selective kinase inhibitors. Small-molecule inhibitors of Interleukin-2-inducible T-cell kinase (Itk) that are based on the 3-aminopyridin-2-one fragment 1 have been reported. Despite derivatisation of 1 y
-
Aminoglutethimide first generation aromatase inhibitor has b
2024-03-05
Aminoglutethimide, first generation aromatase inhibitor, has been tried as an antiepileptic drug in combination with other standard drugs (Aguilar et al., 1961). Letrozole is a third generation reversible non-steroidal aromatase inhibitor, approved by US-FDA, for the treatment of postmenopausal wome
15647 records 161/1044 page Previous Next First page 上5页 161162163164165 下5页 Last page